finerenone + SGLT2 inhibitors

**Finerenone + SGLT2 inhibitors** is a combination therapy under clinical investigation for chronic kidney disease (CKD) and type 2 diabetes (T2D), comprised of finerenone—a selective, nonsteroidal mineralocorticoid receptor antagonist (MRA)—with any member of the sodium–glucose cotransporter 2 inhibitor class (SGLT2 inhibitors, such as empagliflozin, dapagliflozin, canagliflozin, ertugliflozin, or sotagliflozin)[1][2][3]. Both agents act via distinct mechanisms: finerenone antagonizes the mineralocorticoid receptor to reduce inflammation, fibrosis, oxidative stress, and improve endothelial function[2][4]; SGLT2 inhibitors block renal glucose reabsorption, induce glycosuria, and exert cardiorenal protective effects through hemodynamic changes, reduced proteinuria, and potential antifibrotic actions[3]. Preclinical and clinical data support additive or complementary benefits on renal and cardiovascular outcomes when these drugs are combined[1][2][3]. This combination is primarily being studied in CKD and T2D, notably in the CONFIDENCE phase 2 trial[1].

Brand names

Kerendia

Other names

finerenone and SGLT2 inhibitorsfinerenone plus SGLT2 inhibitorfinerenone + empagliflozin